德克萨斯州西南大学医学中心的Milton Packer报告了一个多中心、有安慰剂对照的试验性研究REVIVE Ⅱ的结果。该研究入选了600名左心室射血分数(LVEF)≤35％的心衰住院患者,他们接受Ⅳ利尿剂治疗后仍然有休息状态下的呼吸困难。患者随机接受试验性组合药物治疗与单纯的标准治疗。患者住院第一天接收标准治疗加钙增敏剂 levosimendan．5天后的结果显示,使用levosimenda的患者出现了33％的临床改善,同时还使临床恶化的危险降低 Milton Packer of the Southwestern University Medical Center in Texas reported the results of a multi-center, placebo-controlled, experimental study of REVIVE II. The study enrolled 600 hospitalized HF patients with a LVEF ≤ 35% who had breathlessness after their IV diuretic therapy. Patients were randomized to receive experimental combination therapy with standard therapy alone. Patients received standard treatment plus calcium sensitizer levosimendan on the first day of hospitalization. The results after 5 days showed that 33% of patients in the levosimenda group experienced a clinical improvement while also reducing the risk of clinical deterioration